Cellceutix has received rare pediatric disease designation from the FDA for Kevetrin to treat retinoblastoma, according to a press release.“Receiving the rare pediatric disease designation strengthens our portfolio and adds to our belief that Kevetrin has the potential to provide a meaningful therapeutic benefit to children and families affected by retinoblastoma, where enucleation of the eye is often the only solution,” Leo Ehrlich, CEO of Cellceutix, said in the release.
MILAN–(BUSINESS WIRE)–La société biopharmaceutique Dompé a annoncé aujourd’hui que le Comité des Médicaments orphelin de l’Agence européenne du Médicament (EMA) a désigné officiellement le facteur de croissance du nerf humain recombinant (rhNGF) – la molécule biotechnologique expérimentale développée par Dompé sur la base des recherches effectuées par la lauréate du Prix Nobel Rita Levi Montalcini – comme étant un médicament orphelin pour le traitement de la kératite neurotrophique. Le facteu
MINNETONKA, Minn.–(BUSINESS WIRE)–UnitedHealthcare Vision and Dental plans each rank highest in customer satisfaction, according to the J.D. Power 2015 Vision Plan And Dental Plan Satisfaction Report.
LAS VEGAS — At the American Academy of Ophthalmology annual meeting, Francis S. Mah, MD, talks about the new extended range of astigmatism correcting IOLs from Abbott Medical Optics. The lenses range up to 4.75 D within the corneal plane, which represents “a huge amount of astigmatism that can now be treated,” according to Mah.
ALPHARETTA, Ga.–(BUSINESS WIRE)–Clearside Biomedical, a clinical-stage biopharmaceutical company developing innovative first-in-class drug therapies for diseases of the eye, announces completion of $20 million Series C financing.
MILAAN–(BUSINESS WIRE)–Het biofarmaceutisch bedrijf Dompé heeft vandaag aangekondigd dat het Comité voor weesgeneesmiddelen van het Europees Geneesmiddelenbureau (EMA) de recombinante humane zenuwgroeifactor (rhNGF) – het experimentele biotech molecuul ontwikkeld door Dompé op basis van onderzoek door Nobelprijswinnaar Rita Levi Montalcini – officieel heeft aangeduid als een weesgeneesmiddel voor de behandeling van neurotrofe keratitis. NGF is de eerste neurotrofe factor die geïdentificeerd e